The Scottish Medicines Consortium (SMC) has accepted Libtayo (cemiplimab) for use on the National Health Service (NHS) as a second-line monotherapy for adults with recurrent or metastatic cervical cancer.  It is approved in patients who have disease progression on or after platinum-based chemotherapy, irrespective of PD-L1 expression level or tumour histology.  Although cervical cancer is […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!